Second-To-Market Strategy In HCV: An Interview With AbbVie’s Barry Bernstein
Executive Summary
With Gilead’s Sovaldi already on the market offering major improvements in cure rates for genotype 1 HCV patients, AbbVie must make the best of a potential silver medal. VP of Infectious Diseases Barry Bernstein explains that AbbVie’s Phase III program will provide clinicians detailed information on what regimen should work best for the various patient cohorts within genotype 1 of the virus.